3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Conditions
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
8
Pemetrexed
8
capmatinib
7
Carboplatin
7
ceritinib
5
Cisplatin
5
Bevacizumab
4
Docetaxel
3
trametinib
2
motexafin gadolinium
2
aldesleukin
2
Vinorelbine
2
Paclitaxel
2
Interleukin-2
2
Gefitinib
2
BID protein, human
2
technetium 99m etarfolatide
1
spartalizumab
1
sintilimab
1
satraplatin
1
ribociclib
1
picropodophyllin
1
nazartinib
1
naporafenib
1
milademetan
1
lazertinib
1
fludarabine phosphate
1
fludarabine
1
farletuzumab
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma of Lung
×
AZD5305
×
Clear all
NCT05797168
2026-06-03
FONTANA
AstraZeneca
Phase 1/2
Recruiting
506 enrolled